Dravet Syndrome: Definition and Clinical Overview
Dravet syndrome is a severe developmental and epileptic encephalopathy characterized by onset of pharmacoresistant seizures before 1 year of age (typically prolonged generalized tonic-clonic or hemiclonic seizures), often triggered by fever, vaccination, or photic stimulation, with initially normal development that progresses to intellectual disability, motor impairments, and behavioral abnormalities 1, 2.
Genetic Basis and Diagnosis
Dravet syndrome is primarily caused by loss-of-function mutations in the SCN1A gene (voltage-gated sodium channel alpha-1 subunit), which was confirmed as the genetic cause in 2001 1. These mutations result in haploinsufficiency with decreased function of Nav1.1 sodium channels in GABAergic inhibitory interneurons 3.
Diagnosis should be confirmed through genetic testing for SCN1A mutations, though clinical diagnosis can be made based on the characteristic seizure pattern, age of onset, and developmental trajectory 4, 2.
Key Diagnostic Features:
- Seizure onset: Before 12 months of age (median 3-6 months)
- Initial seizure type: Prolonged hemiclonic or generalized tonic-clonic seizures, often febrile
- Evolution: Development of multiple seizure types including myoclonic seizures, atypical absences, and focal seizures
- Developmental trajectory: Normal early development followed by cognitive stagnation or decline
- Specific triggers: Fever, hyperthermia, vaccination, photic stimulation, pattern stimulation 1, 2
Clinical Manifestations and Comorbidities
Beyond seizures, patients develop a constellation of debilitating comorbidities that significantly impact quality of life:
Neurological and Developmental:
- Intellectual disability: Moderate to severe in most cases
- Motor impairments: Including characteristic crouching gait that develops over time
- Executive dysfunction: Reported in approximately 80% of patients 5
- Language impairment: Particularly expressive language, with relative preservation of receptive abilities 5
- Visuospatial deficits: Present in over two-thirds of patients 5
Behavioral and Psychiatric:
- Behavioral abnormalities and psychiatric comorbidities in over 50% of patients
- Autistic features
- Sleep disturbances 1, 5
Life-Threatening Complications:
- High risk of sudden unexpected death in epilepsy (SUDEP): Particularly elevated in the first 12 years of life 1, 6
- Status epilepticus: Recurring problem, especially in early childhood 7
Treatment Approach
Complete seizure freedom is rarely achievable; treatment goals focus on balancing seizure burden reduction against medication adverse effects while addressing comorbidities 7, 2.
Critical Treatment Principle:
Avoid sodium channel blocking agents (carbamazepine, lamotrigine, phenytoin) as they typically worsen seizures in Dravet syndrome 7, 2.
First-Line Pharmacotherapy:
Clobazam and valproic acid are accepted first-line agents, though they rarely provide adequate seizure control as monotherapy 7, 2.
Evidence-Based Add-On Therapies:
Stiripentol: FDA-approved for adjunctive use in patients ≥6 months old when added to clobazam and/or valproate. Clinical trials and real-world data demonstrate high rates of seizure control, including freedom from status epilepticus for extended periods 6, 2. Stiripentol inhibits drug-metabolizing enzymes, enhancing efficacy of coadministered antiseizure medications 6.
Cannabidiol (Epidiolex): FDA-approved pharmaceutical-grade CBD oil showing efficacy in phase 3 trials 8, 3.
Fenfluramine: Demonstrated excellent efficacy in phase 3 studies 3, 7.
Other beneficial agents:
Non-Pharmacological Interventions:
Status Epilepticus Management:
All patients must have a home rescue benzodiazepine and a written seizure action plan outlining when to administer rescue therapy and steps for hospital management if seizures persist 7.
Prognosis and Long-Term Management
The prognosis remains poor despite treatment advances. Even with polytherapy, only approximately 10% of patients achieve adequate seizure control 3. The condition is associated with:
- Progressive neurodevelopmental impairment
- Persistent cognitive decline that current treatments fail to prevent 1
- High mortality risk, particularly from SUDEP 1, 6
Early intervention is critical, as optimal seizure treatment may improve outcomes, though neurodevelopmental impairments result from both the underlying genetic variant and the epilepsy itself 2.
Emerging Therapies:
The treatment landscape is evolving toward disease modification rather than purely symptomatic control. Agents in development include:
- Gene-regulatory approaches
- Antisense oligonucleotide therapy
- Adenoviral vector therapy
- Selective sodium channel modulators and activators
- TAK935, lorcaserin, clemizole, huperzine analogs, ataluren 3, 9
Future precision medicine approaches should integrate early genetic screening, pharmacogenomic-guided prescribing, patient-specific variant modeling, and targeted gene-modifying therapies to address not only seizures but also communication, learning, mobility, sleep, and autonomic stability 9.